Acute myocardial infarction with lung cancer during treatment with gefitinib: The possibility of gefitinib-induced thrombosis

被引：17
|
作者：
Yamaguchi, K [1 ]
Kanazawa, S [1 ]
Kinoshita, Y [1 ]
Muramatsu, M [1 ]
Nomura, S [1 ]
机构：
[1] Kansai Med Univ, Dept Internal Med 1, Osaka 5708507, Japan
来源：
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS | 2005年 / 34卷 / 01期
关键词：
D O I：
10.1159/000088548
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：48 / 50
页数：3
相关论文
共 50 条
  • [41] Safe and Successful Treatment With Erlotinib After Gefitinib-Induced Hepatotoxicity: Difference in Metabolism As a Possible Mechanism
    Kijima, Takashi
    Shimizu, Tomohito
    Nonen, Shinpei
    Furukawa, Mitsugi
    Otani, Yasushi
    Minami, Toshiyuki
    Takahashi, Ryo
    Hirata, Haruhiko
    Nagatomo, Izumi
    Takeda, Yoshito
    Kida, Hiroshi
    Goya, Sho
    Fujio, Yasushi
    Azuma, Junichi
    Tachibana, Isao
    Kawase, Ichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) : E588 - E590
  • [42] Successful EGFR-TKI Rechallenge of Leptomeningeal Carcinomatosis after Gefitinib-induced Interstitial Lung Disease
    Nakamichi, Shinji
    Kubota, Kaoru
    Horinouchi, Hidehito
    Kanda, Shintaro
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Tamura, Tomohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (04) : 422 - 425
  • [43] Fuzheng Kang-Ai decoction enhances the effect of Gefitinib-induced cell apoptosis in lung cancer through mitochondrial pathway
    Wang, Sumei
    Peng, Zhiwei
    Li, Wenjuan
    Long, Shunqin
    Xiao, Shujing
    Wu, Wanyin
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [44] Enhanced gefitinib-induced repression of the EGFR pathway by ATM kinase inhibition in non-small-cell lung cancer cells
    Tashiro, Satoshi
    Misumi, Keizo
    Sun, Jiying
    Okada, Morihito
    CANCER SCIENCE, 2018, 109 : 472 - 472
  • [45] Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report
    Liang, Yi-Chen
    Wu, Gang
    Cheng, Jing
    Yu, Dan-Dan
    Wu, Hong-Ge
    ONCOLOGY LETTERS, 2015, 10 (03) : 1277 - 1280
  • [46] STAT6 polymorphism was correlated with gefitinib-induced diarrhea in patients with non-small cell lung cancer.
    Guan, Shaoxing
    Chen, Xi
    Chen, Youhao
    Huang, Min
    Zhang, Li
    Wang, Xueding
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Molecular hydrogen attenuates gefitinib-induced exacerbation of naphthalene-evoked acute lung injury through a reduction in oxidative stress and inflammation
    Terasaki, Yasuhiro
    Suzuki, Tetsuya
    Tonaki, Kozue
    Terasaki, Mika
    Kuwahara, Naomi
    Ohsiro, Jumi
    Iketani, Masumi
    Takahashi, Mayumi
    Hamanoue, Makoto
    Kajimoto, Yusuke
    Hattori, Seisuke
    Kawaguchi, Hideo
    Shimizu, Akira
    Ohsawa, Ikuroh
    LABORATORY INVESTIGATION, 2019, 99 (06) : 793 - 806
  • [48] Estrogen Replacement in Female Lung Cancer During Gefitinib Therapy
    Wang, Ping-huai
    Wang, Hao-chien
    Tsai, Chien-chen
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (12) : 829 - 832
  • [49] Gefitinib for the treatment of non-small-cell lung cancer
    Campbell, Lynn
    Blackhall, Fiona
    Thatcher, Nicholas
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (08) : 1343 - 1357
  • [50] Gefitinib for the treatment of non-small-cell lung cancer
    Hida, Toyoaki
    Ogawa, Shizu
    Park, Jang Chul
    Park, Ji Young
    Shimizu, Junichi
    Horio, Yoshitsugu
    Yoshida, Kimihide
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (01) : 17 - 35
12345